Macular Degeneration (AMD) and Diabetic Retinopathy (DR): World Drug Market 2011-2021

Additional Information

Report Excerpt

4.4.4 Forecast for the Spanish Market, 2011-2021

The fourth-largest AMD and DR pharmaceuticals market in Europe and the sixth-largest globally in 2010, the Spanish market, will face significant cost-containment pressures throughout the forecast period of this report. The country embarked on an overhaul of the health system in 2010, targeting savings of between $3bn and $4bn through these reforms. Central to the reforms were a change to the national reference price system for pharmaceuticals and the creation of a central purchasing agency. Along with mandatory price discounts on reimbursed pharmaceutical products decreed by the 2010 overhaul, these measures are designed to reduce the cost of pharmaceutical products in Spain. Pharmaceuticals are already lower-priced in Spain than in other European countries, and the national health service already pays no more than 60% of the cost of prescriptions, individual patients having to pay for the outstanding costs. Spanish healthcare spending nevertheless reached 9.0% of GDP in 2010, higher than the UK and Japan, among the industrialised Western nations. The Spanish attempts to reduce healthcare expenditure have been some of the most extensive and dramatic seen in Europe since the global economic situation worsened in 2008.

Companies Listed

Abbott Laboratories
Advanced Vision Science
Agency for Nutrition and Food Safety (Spain)
Alcon Laboratories
Alimera Sciences
Allergan
American Academy of Ophthalmology (AAO)
American Society of Retina Specialists (ASRS)
AmpliPhi Biosciences Corporation
Assogenerici (Italian Association of Generic Medicines Industry)
Astellas Pharma
AstraZeneca
Aurobindo Pharma
Bausch & Lomb
Bayer Healthcare
Biocon
BioDiem
BioInvent International
Bristol-Myers Squibb
Cambridge University
Centre for Molecular and Vascular Biology, KU Leuven
CIBA Vision
Cipla
Claris Lifesciences
CoMentis
Control Delivery Systems
Daiichi Sankyo
Delenex Therapeutics
Diabetic Retinopathy Clinical Research Network (DRCR)
Dr. Reddy's Laboratories
Eli Lilly
Emory University
ESBATech
Esteve
European Medicines Agency (EMA)
Eyetech Pharmaceuticals
Food and Drug Administration (US FDA)
Fovea Pharmaceuticals
Gene Signal
Genentech
GenVec
GlaxoSmithKline
Harvard Medical School
iCo Therapeutics
Institute of Experimental Medicine (St. Petersburg, Russia)
Intas Biopharmaceuticals
International Diabetes Foundation
Isis Pharmaceuticals
ISTA Pharmaceuticals
Jerini
Joslin Diabetes Center
KAI Pharmaceuticals
Lpath
Ludwig-Maximilians-Universität
Lupin Pharma
MacuSight
MedImmune
Merck & Co.
Merial
National Eye Institute (NEI)
National Health Service (NHS)
National Institute for Clinical Excellence (NICE)
Neurotech
New England Journal of Medicine (NEJM)
Nobilon International
Novartis
Novo Nordisk
Oklahoma Medical Research Foundation
OM Pharmaceuticals
Onco Therapies
Ophthotech
Opko Health
Othera Pharmaceuticals
Oxford BioMedica
Oxigene
Pfizer
Piramal Healthcare
PlaNrt Finance
Potentia Pharmaceuticals
Provincial Institute for the Control of Pharmaceutical and Biologic Products (China)
pSivida
Purdue University
QLT
Quark Pharmaceuticals
Ranbaxy Laboratories
Regeneron
Reliance Life Sciences
ReVision Therapeutics
Roche
Sanofi
Santen Pharmaceutical
Sanwa Kagaku Kenkyusho (a subsidiary of Suzuken)
Shandong University
Shanghai Institute for Biological Sciences
Shire
Silence Therapeutics
Sirion Therapeutics
Sirna Therapeutics
Sirnaomics
State Food and Drug Administration (China)
Strides Arcolab
SurModics
Symphony ViDA
Takeda Pharmaceutical Company
TargeGen
ThromboGenics
University College London
University of Florida
University of Kentucky College of Medicine
Vitreoretinal Technologies
Wockhardt
World Health Organization (WHO)